---
title: "\"Profit Warning\" CSPC PHARMA's revenue declines, expects to earn 45%-60% less for the year"
description: "CSPC PHARMA issued a profit warning, expecting that the profit for the fiscal year 2025 will decrease by 45%-60% compared to the previous year's profit of 1.061 billion yuan. This is mainly due to the"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276340734.md"
published_at: "2026-02-19T13:48:52.000Z"
---

# "Profit Warning" CSPC PHARMA's revenue declines, expects to earn 45%-60% less for the year

> CSPC PHARMA issued a profit warning, expecting that the profit for the fiscal year 2025 will decrease by 45%-60% compared to the previous year's profit of 1.061 billion yuan. This is mainly due to the absence of large-scale epidemics domestically, coupled with medical insurance cost control leading to a decline in terminal sales of drugs, the expansion of the scope of volume-based procurement, and intensified domestic and international industry competition resulting in sustained price pressure, as well as the fact that the bromhexine hydrochloride injection will no longer be sold through the national drug procurement

CSPC PHARMA (02005.HK) issued a profit warning, expecting that the profit for the fiscal year 2025 will decrease by 45%-60% compared to the previous year's profit of 1.061 billion yuan. This is mainly due to the absence of large-scale epidemics domestically, coupled with medical insurance cost control leading to a decline in terminal sales of pharmaceuticals, the expansion of the scope of volume-based procurement, and intensified domestic and international industry competition resulting in sustained price pressure, as well as the discontinuation of the sales of bromhexine hydrochloride injection through the national drug procurement

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Towa Pharmaceutical (TSE:4553) Margin Firmness Reinforces Defensive Earnings Narrative In Q3 2026 | Towa Pharmaceutical (TSE:4553) reported solid Q3 2026 results with revenue of ¥73.6b and net income of ¥8.9b, reflecting | [Link](https://longbridge.com/en/news/275991027.md) |
| Fair drug pricing requires legislation, not executive orders | The article argues that fair drug pricing requires legislation rather than executive orders, highlighting the limitation | [Link](https://longbridge.com/en/news/276261541.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/en/news/276113491.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.